The estimated Net Worth of Dustin S Sjuts is at least $3.51 million dollars as of 15 March 2024. Mr. Sjuts owns over 9,211 units of Revance Therapeutics Inc stock worth over $1,102,479 and over the last 5 years he sold RVNC stock worth over $1,606,029. In addition, he makes $801,023 as Chief Commercial Officer et Aesthetics & Therapeutics at Revance Therapeutics Inc.
Sign up
Mr. Sjuts RVNC stock SEC Form 4 insiders trading
Dustin has made over 4 trades of the Revance Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 9,211 units of RVNC stock worth $46,423 on 15 March 2024.
The largest trade he's ever made was selling 21,508 units of Revance Therapeutics Inc stock on 22 September 2022 worth over $679,438. On average, Dustin trades about 1,719 units every 23 days since 2019. As of 15 March 2024 he still owns at least 167,550 units of Revance Therapeutics Inc stock.
You can see the complete history of Mr. Sjuts stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dustin Sjuts biography
Dustin S. Sjuts serves as Chief Commercial Officer, Aesthetics & Therapeutics of the Company. He was Vice President of Strategy and Sales of the Company. Mr. Sjuts will head all product sales activities, championing strategies to enhance physician relations and drive new product adoption. Most recently, he held leadership positions at Nestle Skin Health, including Business Unit Head in China and Senior Director of Marketing in the U.S. In China, he was responsible for the medical aesthetics commercial organization, leading the development and execution of the medical solutions strategy. Prior to this, Mr. Sjuts was Senior Vice President of Franchise Operations for Alphaeon. Previously, he served as Director of Sales in Eye Care and as Senior Regional Manager of Aesthetics at Allergan.
What is the salary of Dustin Sjuts?
As the Chief Commercial Officer et Aesthetics & Therapeutics of Revance Therapeutics Inc, the total compensation of Dustin Sjuts at Revance Therapeutics Inc is $801,023. There are 4 executives at Revance Therapeutics Inc getting paid more, with Mark Foley having the highest compensation of $17,190,400.
How old is Dustin Sjuts?
Dustin Sjuts is 40, he's been the Chief Commercial Officer et Aesthetics & Therapeutics of Revance Therapeutics Inc since 2019. There are 15 older and no younger executives at Revance Therapeutics Inc. The oldest executive at Revance Therapeutics Inc is Robert Byrnes, 75, who is the Independent Director.
What's Dustin Sjuts's mailing address?
Dustin's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, 20TH FLOOR, NASHVILLE, TN, 37203.
Insiders trading at Revance Therapeutics Inc
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli et Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
What does Revance Therapeutics Inc do?
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
What does Revance Therapeutics Inc's logo look like?
Complete history of Mr. Sjuts stock trades at Revance Therapeutics Inc
Revance Therapeutics Inc executives and stock owners
Revance Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Foley,
President, Chief Executive Officer, Director -
Abhay Joshi,
Chief Operating Officer, President - R&D and Product Operations -
Tobin Schilke,
Chief Financial Officer -
Mark J. Foley,
CEO & Director -
Dustin Sjuts,
Chief Commercial Officer, Aesthetics & Therapeutics -
Dr. Abhay Joshi,
COO, Pres of R&D and Product Operations -
Dustin S. Sjuts,
Pres -
Tobin C. Schilke,
CFO & Principal Accounting Officer -
Chris Nolet,
Independent Director -
Jill Beraud,
Independent Director -
Angus Russell,
Independent Chairman of the Board -
Robert Byrnes,
Independent Director -
Philip Vickers,
Independent Director -
Phyllis Gardner,
Independent Director -
Julian Gangolli,
Independent Director -
Jeanie Herbert,
Sr. Director, Investor Relations -
Aubrey Rankin,
Director -
Dwight Moxie,
Senior Vice President, General Counsel, Corporate Secretary -
Azita Nejad,
Sr. VP of Technical Operations -
Justin Ford,
Sr. VP of HR & Head of People -
Taryn Conway,
VP of Marketing -
Jessica Serra,
Head of Investor Relations & ESG -
L Daniel Browne,
CEO and President -
James Walter Glasheen,
Director -
Ronald W Eastman,
Director -
Mark A Sr Prygocki,
Director -
Todd Erik Zavodnick,
CCO & President, -
Cyril Allouche,
Principal Accounting Officer -
Caryn Gordon Mc Dowell,
SVP, GC & Secretary -
Jacob Waugh,
Chief Scientific Officer -
Jonathan Tunnicliffe,
Director -
Ronald J Wooten,
Director -
Woodlands Health Ventures F...,
-
Arthur Peter Bertolino,
EVP and Chief Medical Officer -
Pharma Opportunities Fund I...,
-
Lauren P Silvernail,
CFO, Secretary & EVP Corp Dev. -
Curtis Ruegg,
EVP, Technical Operations -
Olivia C Ware,
Director -
Carey O Connor Kolaja,
Director -
Erica Jordan,
Chief Commercial Officer -
Vlad Coric,
Director